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SUMMARY 
Background: Dengue fever (DF) and Dengue Hemorrhagic fever’s (DHF) lack of an effective vaccine and 
specific treatment promotes the diseases’ significance as a public health problem leading to increased 
morbidity and mortality. The disease is caused by any four closely-related, but antigenically distinct, Dengue 
virus (DENV) serotypes; DENV-1, DENV-2, DENV-3, and DENV-4 transmitted through mosquito vectors, 
Aedes mosquitoes. Currently, there is scanty information on its incidence and prevalence in populations 
naturally-exposed to mosquito-borne diseases in western Kenya.  
Methods:  This study was therefore designed to determine the sero-prevalence of DF in patients (n=422, 
aged>5 years) presenting with fever at three selected health facilities in Kenya; Anderson Medical Centre (in 
Trans-Nzoia District in Rift Valley Province), and KEMRI/CIPDCR Alupe Clinic and Alupe Sub-district Hospital 
(in Teso-south District of Western Province).  Furthermore, the socio-demographic characteristics associated 
with potential risk on sero-prevalence of dengue virus were evaluated. Using serum, indirect ELISA was 
performed as the screening test with Plaque Reduction Neutralization Test (PRNT) as the confirmatory test, 
while sociodemographic characteristics were evaluated using structured questionnaires. Chi-square tests 
were used to test for proportionality.  
Results: Overall, a low sero-prevalence of 1.2% (5/422) was recorded in the two regions. Among the main 
significant symptoms of classical DF were retro-orbital pain (OR; 7.75, 95% CI; 1.25-48.07, P=0.013), 
muscle ache (OR; 10.89, 95% CI; 1.20-78.50, P=0.016) and joint pain (OR; 53.47, 95% CI; 1.22-45.32, 
P=0.009). In addition, walls with cracks (OR; 8.75, 95% CI; 1.43-2.389, P<0.001), place of storage of water 
vessel (OR; 3.20, 95% CI; 2.78-68.10, P=0.014), burning of charcoal (OR; 0.06, 95% CI; 0.01-0.38, 
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P<0.001) and farming (OR; 8.83, 95% CI; 1.97-79.78, P<0.001) were significantly associated with DENV-2 
sero-positivity. The current study identifies additional factors that may predispose to DF in populations 
naturally-exposed to mosquito-borne diseases.  
Conclusion: The overall seroprevalence was low but non-zero implying that dengue is not a main cause of 
febrile illness in these study regions, but it may be a potential hazard to public health. 
Key words: sero-prevalence, dengue virus, health facilities, Kenya 
[Afr J Health Sci. 2013; 26:248-271] 
Introduction 
Dengue is a mosquito-borne viral infection that in 
recent decades has become a major international 
public health concern [1]. Dengue is found in tropical 
and sub-tropical regions around the world, 
predominantly in urban and semi-urban areas [1]. For 
the last 50 years throughout tropical and sub-tropical 
regions around the world Dengue fever epidemics has 
reoccurred together with an emergence of dengue 
hemorrhagic fever (DHF) and dengue shock syndrome 
(DSS), [2, 3]. The global renaissance of dengue has 
been implicated with several factors, for instance: - 
failure to control the Aedes populations, increased 
airplane travel to dengue endemic areas, uncontrolled 
urbanization, and an unprecedented population growth 
[3, 4]. The worldwide incidence is estimated to be 50 
to 100 million cases of dengue fever (DF) and several 
hundred thousand cases of dengue hemorrhagic fever 
(DHF) per year [1]. DHF is more serious and the 
fatality rate is about 5% [1]. 
Arbovirus epidemics have sporadically occurred across 
regions of Kenya, but limited efforts have been put on 
the surveillance during these epidemics. Dengue virus 
serotype 2 was initially isolated from patients along the 
coast of Kenya in 1982 [5], and later identified in 
samples from a serology survey in subsequent years 
suggesting a more extensive circulation of the virus 
than is currently documented [6]. A study conducted in 
Kenya between the years 2000-2004, on the serologic 
evidence of arboviral infections among humans 
revealed DENV-2 to be the most common dengue 
serotype in Kenya, followed by DENV-1, DENV-3 and 
then DENV-4 [7]. As such, the current study focused 
on DENV-2 since previous observations have 
demonstrated that it is the most common circulating 
serotype in Kenya. 
However, it is critical to point out that cross-reactivity 
among flaviviruses prevents conclusive determinants of 
which dengue serotypes are circulating in Kenya. In 
addition, information from previous studies has 
demonstrated that DENV-2 is endemic to Kenya and 
Somalia, with traces of DENV-1 and DENV-3 being 
found in nearby Somalia [6] . Given the inter-
continental connections routes between Kenya and 
other countries where dengue is perceived to be 
endemic, the circulation of multiple DENV serotypes is 
not unexpected [7]. 
Despite these observations [7], no documentation on 
outbreaks has been reported in Rift Valley and 
Western Provinces of Kenya, two regions 
predominated with the mosquito vectors A. Aegypti, the 
documented causative agent for dengue and other 
flavivirus [6], [8]. 
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Global documentation of the prevalence and sero-
prevalence studies have been and are still being 
conducted on dengue worldwide [3] underscoring the 
health importance of dengue. 
Most of these studies suggest that the global 
prevalence of dengue has grown dramatically in recent 
decade [9]. In Kenya, fewer studies have been 
conducted on dengue, for example, a sero-survey 
conducted during September 1987 for evidence of 
human arboviral infections in the Coast Province of 
Kenya [10] revealed a prevalence rate of 1.0% for 
dengue 2 viruses. 
Additional studies conducted in western Kenya in 
Kisumu, found a prevalence of 1.1% for dengue 2 
[11]. These studies demonstrate paucity of knowledge 
on the actual prevalence of dengue in Kenya, and 
whether or not it is endemic in Kenya. 
In P. falciparum holoendemic transmission regions 
such as in western Kenya, studies have revealed that 
A. Aegypti are found in large populations [12]. 
However, little efforts have been made in the 
identification and transmission cycles of these vectors 
associated with dengue in such holoendemic regions. 
In addition, there has been limited surveillance and 
reports on severe forms of dengue since the disease is 
assumed to be of little health importance. 
Furthermore, most DENV human infections are self-
limiting and sub-clinical, and are thus, often 
misdiagnosed in Kenya [13]. 
Trans-Nzoia District of Rift-Valley Province and Teso-
south District region of Western Province are areas 
that are naturally exposed to arthropod borne 
diseases. Previous unreported studies carried out in 
Kenya demonstrated high levels of alpha virus 
exposure, however, no formal studies have been 
performed in this region. In addition, despite the fact 
that the vectors associated with transmission of 
dengue exist in this region, no studies have been 
carried out to determine the sero-prevalence of 
dengue in febrile persons presenting in the two 
regions. Therefore, the current study used indirect 
enzyme-linked immunosorbent assay (ELISA) as a 
screening test and Plaque Reduction Neutralization 
Test (PRNT) as a confirmatory test, to determine the 
sero-prevalence of dengue in febrile patients visiting 
three selected health facilities in Western and Rift 
Valley Provinces, Kenya. 
Demographic, economic, behavioral and social factors 
play key roles for effective communicable disease 
control and underpin successful public health programs 
[14], however, the role of these factors in predisposing 
to dengue virus transmission is still poorly understood 
since most studies performed in the context of dengue 
have been inconclusive and inconsistent [14]. For 
example, studies conducted in Asia, demonstrated that 
severe forms are mostly experienced in children under 
15 years of age [15], [16], whereas in the Americas, 
the dengue syndromes are experienced in all age 
groups with most fatalities being experienced in 
children [3]. Some population-based studies have also 
shown dengue to be more severe and common in 
females than males [17]; [18] . Other socio-
demographic characteristics such as education, 
occupation, marital status and place of habitat have 
also been assessed in some studies [19] but limited to 
Africa. Since no studies have been carried out in Africa 
to assess the risk factors associated with dengue, the 
current study used a basic questionnaire to obtain the 
individual level risk factors, household-level risk 
factors, socioeconomic activities, use of insect treated 
nets (ITNs), use of other vectors control-level risk 
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factors and yellow fever vaccination in the past ten 
years to identify the potential risk factors on sero-
prevalence of DENV in two regions in Kenya. 
The clinical picture of dengue fever in infants and 
young children is often associated with a non-specific 
febrile illness that can hardly be differentiated from 
other viral illnesses [3]. 
However, more severe cases of dengue fever are 
usually seen in older children and are characterized by 
a rapidly rising temperature (≥ 39°C) that lasts 5-6 
days [20]. Hence, the current study recruited 
participants who were ≥5 years of age. The febrile 
period is usually accompanied by severe headache, 
retro-orbital pain, myalgia, arthralgia, nausea and 
vomiting [1], [3], [20]. Over half of the infected people 
report a rash during the febrile period that is initially 
macular or maculopapular and becomes diffusely 
erythematous [13], [21]. Minor haemorrhagic 
manifestations like petechae, epistaxis and gingival 
bleeding do occur, however, severe haemorrhage is 
unusual [13], [21]. Therefore, the current study also 
determined the clinical characteristics of people with 
dengue antibodies in the two study regions. 
 
 
 
Methods 
Study design: This was a descriptive study using 
prospective hospital-based surveillance for cases 
presenting with fever at the three selected health 
facilities; Alupe Sub-district Hospital, 
KEMRI/CIPDCR Alupe Clinic both of Teso-south 
District and Anderson Medical Clinic of Trans-Nzoia 
District, in western Kenya. The surveillance and 
laboratory testing was done to identify antibodies 
associated with DENV-2 infection and characterize the 
epidemiological and clinical characteristics of DENV-2 
infection at participating hospitals. 
Population 
Selected Hospitals in Western Kenya: Participants 
were enrolled at three health facilities, serving different 
regions of Kenya: Alupe Sub-district Hospital and 
KEMRI/CIPDCR Alupe 
Clinic both of Teso-south District serve a primarily 
rural area of western Kenya, and Anderson Medical 
Clinic of Trans-Nzoia District serves a wider area 
which includes Cherangani, Kwanza and Saboti 
Constituencies in Rift Valley Province, of Western 
Kenya. These three health facilities are at a close 
proximity to each other and lie along the border belt 
that connects Kenya to Uganda (Figure 1). The three 
health facilities serve both children and adults patients. 
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Figure 1.  Map of Western Kenya (Source: USAID 2009) showing the study sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
Teso-South District: In Teso-South District of 
Western Kenya, two health facilities were involved; 
Alupe Sub-district Hospital (which is the primary health 
care facility) and KEMRI/CIPDCR Alupe Clinic (is the 
secondary heath care facility). Both health facilities are 
in Alupe Division of Teso-south District in Western 
Province. Geographically, they fall on the rural Western 
part of Kenya along the Border belt which borders 
Kenya and Uganda. The population area belongs 
predominantly to the Ateso ethnic group, many of 
whom practice subsistence farming. Alupe Sub-district 
Hospital is a level 3 and is the largest in the District 
and receives referrals from smaller facilities and other 
facilities from Kenya. KEMRI/CIPDCR Alupe Clinic is a 
level 2 health facility; it serves a study health facility for 
clinical studies and also provides health care services 
to the rural population of this region. Being a KEMRI 
health facility, it receives referrals from other health 
facilities in different regions of Western Kenya as well. 
All the laboratory clinical evaluations, virological and 
serological tests were performed at the 
KEMRI/CIPDCR. Medical care was provided to the 
study participants as per Ministry of Health (MoH) 
guidelines. 
Trans-Nzoia District: In this District, only one health 
facility was involved, as it lies on the border belt of 
Kenya and Uganda; Anderson Medical Centre. It 
serves primarily the Mount Elgon region in Trans-
Nzoia District. The hospital receives referrals from 
other facilities as it is well equipped both in 
workmanship and medical equipment. Trans-Nzoia 
District is an administrative District of Rift Valley 
Province, Kenya. The district has three constituencies: 
Cherangani, Kwanza and Saboti. 
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Patient Eligibility and Number of participants 
Persons ≥5 years of age who had fever ≥37.8°C 
presenting to one of the participating hospitals were 
eligible for the study, according to the inclusion criteria 
which involved willingness by the participants or the 
parents/guardians of minors to provide informed 
consent for their children to participate in the study. All 
persons who were unwilling to give consent and assent 
for participating in the study and those who were below 
5 years were excluded from participation. 
Based on a retrospective review of hospital treatment 
logs, it was expected that approximately half of the 
participants to be children ≤13 years of age; the 
remainder being older children and adults. The clinical 
picture of dengue fever in infants and young children is 
often associated with a non-specific febrile illness that 
can hardly be differentiated from other viral illnesses 
(3). However, more severe cases of dengue fever are 
usually seen in older children and are characterized by 
a rapidly rising temperature (≥ 39°C) that lasts 5-6 
days (20). The prevalence of DENV-2 in the two study 
regions of Western Kenya is not known; therefore a P-
value of 50% was used to yield a maximum sample 
size [22]. The sample size used in this study was 
dependent on the desired degree of precision and the 
anticipated prevalence; hence the formula n=Z2PQ/d2 
was used to derive the desired sample size. Where n 
is the desired sample size, P is the expected 
prevalence in the target population with the 
characteristic being measured, Q is 1-P, Z is 1.96; 
standard error (95% confidence level of the standard 
deviation from the mean), d is the level of statistical 
significance (0.05). 
Based on this formula, the estimated sample size was 
384. An additional 10% was sampled to take care of 
missing or inconsistent data collections [23], providing 
a total sample size of 422. As such, a total sample 
size of 140 individuals was to be drawn from each 
facility. There was bias towards KEMRI/CIPDCR Clinic 
as most patients were always referred to this facility 
hence a larger proportion of the participants were 
recruited from KEMRI/CIPDCR ~ 176. 
Sample collection and processing 
Upon presentation to the two study hospitals, 
participants were directed to a trained study nurse, 
who recorded their socio-demographic information 
including gender, age in years, marital status, 
occupation, education and place of habitat, tympanic 
temperature using a standardized questionnaire. Data 
on housing conditions, yellow fever vaccination status, 
and use of bednets were also recorded. Study 
physicians performed a medical examination and 
recorded data systematically on the history of the 
illness and current symptoms, consisting of 20 
variables including headache, retro-orbital pain, joint 
pain, vomiting, lower and upper respiratory symptoms, 
gastrointestinal symptoms, urinary tract symptoms, 
musculoskeletal pain, rashes and hemorrhagic 
manifestations. Data on any medical tests requested 
and treatments prescribed was recorded. 
Blood samples were collected by venipuncture using 
aseptic technique by the study clinician or study nurse. 
At each venipuncture, about 5 ml of blood was 
collected from study participants. These specimens 
were collected in vacutainer serum tubes and 
centrifuged at 1500 rpm for 10 minutes. The tubes 
containing the serum were kept at -20ºC at the 
participating health facilities until collection. Once every 
month, the tubes containing the serum were 
transported in dry ice to KEMRI/CIPDCR laboratories 
where they were processed and tested as soon as 
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possible. The total time taken to transport samples 
from the field to KEMRI did not exceed 48 hours. In 
situations where an urgent diagnosis was necessary, 
for instance in a patient with suspected hemorrhagic 
fever, the serum sample was sent to KEMRI/CMR P3 
labs immediately. 
All laboratory procedures were performed under the 
same experimental conditions. Quality assurance was 
maintained at high standards for each test performed. 
Screening indirect ELISA tests were performed in 2 
months while the PRNT confirmatory tests were 
performed in 4 months. 
Laboratory procedures 
Viruses and Cell lines: Purified Hawaiian strain of 
dengue virus [Dengue type II (DEN-2) (002ST) 2009; 
titre (1×10-5 PFU/ml)], obtained from Nagasaki 
University Institute of Tropical Medicine, was used in 
all serological tests. In addition, the African green 
monkey derived Vero cells kindly supplied by Nagasaki 
University Institute of Tropical Medicine were used as 
cell lines for viral culture. 
Indirect Enzyme-linked Immunosorbent Assay 
(ELISA): Indirect ELISA screening test was performed 
according to an in-house kit method as previously 
described (24) with few modifications to suit the local 
laboratory settings (25). The IgA, IgG, and IgM were 
measured for the determination of the sero-prevalence 
of dengue virus in febrile patients visiting the three 
selected health facilities. In order to make the test 
cells, the DENV-2 antigen was diluted 1:500 in 1× 
Phosphate Buffered Saline (PBS) and 100μl of the 
DENV-2 antigen solution added into a 96-well plate in 
rows A, B, E, F. For the internal control wells, 100μl of 
1×PBS containing 3% Fetal Calf Serum (PBS-F) was 
added into each of the 96-well plates in rows C, D, G, 
H. These wells were used in the experiment to 
distinguish between clear backgrounds after substrate 
reaction. The plates were wrapped in aluminium foil 
and kept in 4°C overnight. The following day, the 
plates were washed four times with 0.05% Tween in 
1×PBS (PBS-T) washing buffer, using an ELISA plate 
washer (Thermoscientific Well Washer, Ratastie 2, 
Ratastie 2, F1-01620 Vantaa, Finland). A 100μl of 
PBS-F solution was then added as blocking solution 
into every well of the plate, and the plates covered with 
parafilm and incubated for 1 hour at room temperature. 
The test sera were then diluted 1:1000 with PBS-F 
and kept on ice. After the first 1-hour incubation 
period, the plates were gently tapped on blotting 
papers to discard the blocking solution completely, 
then 100μl of the diluted test serum was added in 
duplicates into virus antigen and PBS-F pre-coated 
wells. The plates were then incubated for another 1 
hour at 37°C in an incubator. Secondary antibody; 
antihuman IgG+IgM+IgA was diluted 1:5000 in PBS-F 
and kept on ice. After the second 1-hour incubation, 
the plates were washed four times with PBS-T. Then 
100μl of the diluted secondary antibody solution was 
added into each well. The plates were then incubated 
for another 1 hour at 37°C in an incubator. The 
substrate solution [O-phenylenediamine 
dihydrochloride (OPD), SigmaFast tablets] was diluted 
in distilled water (1 tablet each of the buffer and OPD 
into 20ml of distilled water and allowed to dissolve 
completely in the dark). After the third 1-hour 
incubation above, the plates were washed 4 times and 
blotted to dry. A 100μl of the OPD solution was then 
added into each well, preceded by incubation for 15 
minutes at room temperature in the dark. Finally, a 
100μl of 1N sulphuric acid solution was added into 
each well to stop the enzyme-substrate reaction. 
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The plates were then read on an ELISA plate reader 
(Thermoscientific Multiskan ex. Version, Tokyo, Japan) 
at a wavelength of A492nm (Ascent software version 
2.6-Deafulte.See, Shangai, China). The Optical 
Densities (OD) of positive-to-negative (P/N) ratios of 
>1.0 was considered positive, <0.5 was considered 
negative and ≥0.5 was considered borderline positive. 
All sera that were positive and border line for DENV 
indirect ELISA, were further re-tested using the Plaque 
Reduction Neutralization Test (PRNT) to confirm the 
diagnosis according to standard methods (26). 
Plaque Reduction Neutralization Test (PRNT) 
Cell Culture and Resuscitation of frozen Vero cell 
lines: The Vero cells lines were revived and 
maintained at BSL-3 laboratory, in culture media. 
Growth Medium (1×EMEM, 1.1g/L NaHCO3, 10%FCS, 
L-glut/P/S) and Maintenance Medium (1xEMEM, 
1.1g/L NaHCO3, 2%FCS, L glut/P/S) were prepared. 
The T175 NUNC cell culture flasks were labeled 
according to cell line, passage number and date of 
preparation. The vials containing cells (stored in liquid 
nitrogen) was collected and placed in water bath at 
37°C. The cells were allowed to thaw for 1-2 minutes 
until a small amount of ice remained in the vial. The 
vial was then transferred to a safety cabinet where it 
was sterilized and the cap loosened. Cells were slowly 
pipetted drop-wise in centrifuge tubes containing 10ml 
of pre-warmed growth medium to dilute the Dimethyl 
sulphoxide (DMSO). The cells were span at 1500rpm 
for 5 minutes at room temperature to separate DMSO. 
The supernatant was removed and the cells re-
suspended in 10ml of pre-warmed growth medium. 
The cells were then cultivated in T175 culture flasks 
containing 50ml of pre-warmed growth medium, after 
which they were monitored under inverted microscope 
to ensure even distribution prior to incubating at 37°C 
and 5% CO2 for 24 hours to allow cell growth. 
Sub-culture of adherent Vero cell lines: Cultures 
were viewed on an inverted microscope to assess 
degree of confluence and to monitor that bacterial and 
fungal contaminations do not occur. Supernatants 
harvested from the growing cells was removed and 
placed in centrifuge tubes. The cell monolayer formed 
was washed twice with approximately 10ml of 1×PBS. 
Approximately 7ml of trypsin/EDTA solution was added 
onto the washed cell monolayer, ensuring that the flask 
was gently rotated for the trypsin to cover the 
monolayer evenly. The flask was then placed in an 
incubator at 37°C and 5% CO2 for 4 minutes to allow 
for trypsin incorporation by the cells. The cells were 
then examined on an inverted microscope to ensure 
that all the cells are detached and floating. The side of 
the flask was then gently tapped to detach monolayer 
completely and the cells re-suspended with the rest of 
the spent growth medium to inactivate trypsin. Cells 
were then transferred into centrifuge tubes and spun at 
1600rpm for 5 minutes at room temperature. The 
supernatant was discarded and the cells were 
resuspended in 5ml of fresh growth medium, and 
approximately 100μl of cell mixture placed in a cell 
count chamber for counting. Approximately 
1×106cells/ml to 2×105cells/ml were transferred to a 
newly-labeled flask containing pre-warmed medium 
and observed under inverted microscope to ensure 
even distribution and then placed in an incubator at 
37°C and 5% CO2 for ~24-48 hours for them to grow 
further. These sub-cultures were performed for about 
3-4 days to allow the cells to stabilize enough for 
PRNT assays. 
The Plaque Reduction Neutralization Test (PRNT): 
In order to perform PRNT test, 2μl of maintenance 
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medium (MM) was added into each of the 6 well plates 
(Nunc), followed by addition of Vero cells at a 
concentration of 1.2×105 cells/ml to allow seeding in 
each of the wells. Cells were cultured in MM for 1-2 
days at 37°C and 5% CO2 and observed on an 
inverted microscope to assess for 80% confluence. All 
test sera were heat-inactivated at 56°C in a water 
bath for 30 minutes. Two-fold serial dilution for test 
sera, positive and negative controls beginning with 
1:10 (final 1:20) were prepared in MM and added to 
equal volume of virus standards diluted to yield 
200PFU/0.1ml. Virus-serum dilution mixtures of 0.5ml 
total volume were incubated for 60 minutes at 37°C. 
Six-well plates containing 80% confluent Vero cell 
monolayer were labeled in readiness for inoculation. 
One milliliter of the culture medium was aspirated from 
each well and enough residual fluid of ~1ml left to 
prevent the monolayer from becoming dry. One 
hundred microlitres of each of the virus serum mixture 
was added and inoculated into each of the two wells of 
the properly prepared 6-well plates. The virus-serum 
mixture was then evenly distributed by rocking the 
plates back and forth and sideways. The virus-serum 
mixtures together with the cells were incubated for 90 
minutes at 37°C and 5% CO2 for virus absorption to 
take place. After the incubation period, 4ml of overlay 
medium was added into each well and plates were 
incubated at 37°C and 5% CO2 for 5 days (DENV-2) 
to allow plaques to develop. On day 5, the overlay 
medium was aspirated completely using a plastic sero-
pipette attached to a pipette aid. The aspirated overlay 
medium was discarded in 2% Sodium Dodecyl 
Sulphate (SDS) solution and later autoclaved. One 
milliliter of 10% formaldehyde in 1×PBS (1/10 diluted 
formalin with 1×PBS) was added over the cells and the 
plates incubated for 1 hour at room temperature in a 
safety cabinet with ultraviolet light to fix the plates. 
Formaldehyde was completely aspirated and properly 
discarded. The surface of the plates was wiped to 
sterilize before taking them out of the safety cabinet for 
washing. Plates were washed gently with running 
water and absorbed on blotting paper. Half milliliter of 
1% crystal violet solution in water-staining solution 
was added to each well. The plates were placed at 
room temperature for 10 minutes for the cells to 
absorb the dye. The excess dye was discarded and 
the plates were washed gently with tap water, followed 
by absorption on blotting paper and a final air-drying 
at room temperature. Plaques were counted for each 
set of duplicate wells and the percentage reduction 
calculated by comparing against the positive control 
virus well (100% plaque forming units). More than 
90% plaque reduction was regarded as positive. 
Data Management and Analysis: Data obtained from 
the questionnaires were entered and managed in Excel 
spreadsheets. Uniquely-coded samples were noted as 
either DENV negative or DENV-positive. The results 
were categorized as per the DENV antibody status. All 
data were imported in SPSS software v19.0 prior to 
analyses. Data obtained from the PRNTs were also 
categorized as PRNT-positive or PRNT-negative. 
Proportionality tests were used to determine sero-
prevalence of DENV-2. A logistic regression analysis 
was carried out to identify socio-demographic 
characteristics, clinical characteristics and risk factors 
associated with sero-prevalence. Statistical 
significance was determined at P ≤0.05. 
Results 
The sero-prevalence of DENV-2 among study 
participants: A total of 422 serum samples were 
available for DENV serotyping. The DENV serotype 
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test detects the presence of IgM, IgG and IgA DENV 
antibodies. The sera were first subjected to indirect 
ELISA screening test as per WHO recommendations 
[26]. Out of the 422, 14.7% (n=62) were positive for 
DENV antibodies.  Screening test positives per health 
facility was as follows: Alupe Sub district Hospital, 
24.2% (30/124), KEMRI/CIPDCR Alupe Clinic, 13% 
(23/176) and Anderson Medical Clinic, 7.4% (9/122) 
(Table 1).  
A chi-square test demonstrated that proportions of 
those serologically positive across the three different 
sites was statistically significant (P=0.0007) (Table 1). 
These differences were attributed to the highest 
proportions of those serologically positive in Alupe 
Sub-district Hospital (24.2%), with the least being 
observed from Anderson Medical Centre (7.4%). 
Following the establishment of the sero-status, 
serologically-positive samples (n=62) were transported 
in dry ice to Kenya Medical Research Institute/Centre 
for Medical Research (KEMRI/CMR) P3 level 
laboratory, where they were further tested by PRNT for 
confirmation. Results revealed that only 1.2% (n=5) 
were positive by PRNT confirmatory test (Table 2). In 
the current study, sero-positivity was based on the 
presence of neutralizing antibodies specific for DENV-
2. A chi-square test revealed that the distribution of 
those testing positive with the confirmatory test was 
significantly higher in those individuals that tested 
positive with the serological test (P=0.020, Table 2). 
Table 2: Sero-prevalence of DENV Sero-positivity based on PRNT  
Test, n (%) Confirmatory +ve n (%) 
Confirmatory –ve 
n (%) P-value 
Screening serologically +ve (62) 5(8.1) 57(91.9) 
0.020 a 
Screening serologically –ve (362)  0(0) 360(100) 
Total sample size 
422 (100) 5(1.2) * 417(98.8) 
Data are presented as n (%).a=χ2 test. *Only 5 individuals tested positive with PRNT confirmatory test. +ve=positive, 
-ve=negative 
Socio-demographic and Clinical characteristics of 
the study participants 
Socio-demographic characteristics: The socio-
demographic characteristics of the study participants 
who presented with fever at the three selected facilities 
and who tested positive with the serological tests are 
shown in Table 3. A total of 261 children between 
ages 5-12 years, 14 older children between ages 13-
17 years and 147 adults, aged 18 years and above, 
were included in the study. Out of these, 182 
(43.13%) were males while 240 (56.87%) were 
females. When stratified by gender, the DENV sero-
prevalence was 1.7% (4/240) in female and 0.5% 
(1/182) in male patients, however, the sero-
prevalence in males vs. females was comparable 
(P=0.294, Table 3). 
Even though the age for the participants ranged from 
<20 years to > 60 years, those confirmed to be having 
dengue infections were between the ages of 21 to 60 
years. Age was a significant factor in the distribution of 
sero-prevalence in the studied population (P=0.001, 
Table 3). 
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Of the total study population, 133 (31.5%) were 
married, 1 (0.2%) was widowed, 13 (3.1%) were 
single or divorced or separated and the remaining 275 
(65.2%) did not provide marital status (NB: Out of this 
figure 261 were children). All of the 5 individuals 
confirmed to be sero-positive by PRNT were married. 
None of the school-going persons were sero-positive 
for dengue infection. Employed persons were 33 
(7.82%), self-employed 47 (11.14%) and unemployed 
were 73(17.3%). Of the sero-positive individuals, only 
1(3%) was employed, 3(6.4%) were self-employed, 
while 1(1.4%) was unemployed. The prevalence of 
those seropositive was significantly higher in the self-
employed group (6.4%) relative to any other 
occupation (P=0.002, Table 3). Finally, the level of 
education and place of residence did not alter the 
proportions of those sero-prevalent in this population 
(P=0.475 and P=0.337, respectively, Table 3). 
Table 3: Sero-prevalence of DENV according to socio-demographic factors 
Socio-demographic factor Positive,  
n (%) 
Negative,  
n (%)  
P-value OR (95% CI) P-value 
Gender      
Females 4 (1.7) 236 (98.3) 0.294a 3.06 (0.34-27.68) 
NSb 
Males 1 (0.5) 181 (99.5)  1.00 
Age in years (range)      
<20 (n=287) 0 (0.0) 287 (100.0) 0.001a ∞ 
NSb 
21-30 (n=65) 1 (2.0) 64 (98.0)  1.000 
31-40 (n=36) 2 (6.0) 34 (97.0)  3.76 (0.32-42.03) 
41-50 (n=14) 1 (7.0) 13 (93.0)  0.20 (0.01-3.46) 
51-60 (n=10) 1 (10.0) 9 (90.0)  0.14 (0.08-2.45) 
>60 (n=10) 0 (0.0) 10 (100.0)  ∞ 
Marital status      
Married 5 (3.8) 128 (96.2) 0.012a 1.000 
NSb 
Single/divorced/separated 0 (0.0) 13 (100.0)  ∞ 
Widowed 0 (0.0)   1 (100.0)  ∞ 
No marital status given 0 (0.0) 275 (100.0)  ∞ 
Occupation      
Attending school 0 (0.0) 269 (100.0) 0.002a ∞ 
NSb 
Employed 1 (3.0) 32 (97.0)  2.25 (0.13-37.11) 
Self-employed 3 (6.4) 44 (93.6)  4.90 (0.49-48.67) 
Unemployed 1 (1.4) 72 (98.6)  1.000 
Education      
Educated 2 (1.8) 108 (98.2) 0.475a 1.000 
NSb 
Not educated 3 (1.0) 309 (99.0)  1.908 (0.315-11.569) 
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Place of habitation      
Town 0 (0.0) 65 (100.0) 0.337a ∞ NSb 
Rural 5 (1.4) 352 (98.6)  1.000 
Data are presented as n (%).a=χ2 test. b= logistic regression analyses. ∞=infinity. NS=not significant. 
Clinical characteristics and DENV seropositivity: 
Fever was the main inclusion criteria into the current 
study i.e. all the study participants had to present with 
fever to be included in the study. Table 4 presents 
other clinical characteristics of the study participants at 
the time of enrolment. When the clinical characteristics 
were evaluated against sero-prevalence in the 
population, retro-orbital pain (P=0.010), muscle ache 
(P=0.008), and joint pain (P=0.011) significantly 
altered distribution of sero-prevalence in the current 
study. However, headache (P=0.167), vomiting 
(P=0.740), presence of rashes (P=0.447), bleeding 
diathesis (P=0.755) and abdominal pain (P=0.740) did 
not alter the distribution of sero-prevalence in the 
population (Table 4). Further logistic regression 
analyses demonstrated that retro-orbital pain (OR; 
7.75, 95% CI; 1.25-48.07, P=0.013), muscle ache 
(OR; 10.89, 95% CI; 1.20-78.50, P=0.016) and joint 
pain (OR; 53.47, 95% CI; 1.22-45.32, P=0.009) were 
significantly associated with DENV seroposititivity 
(Table 4). These results demonstrate that retro-orbital 
pain, muscle ache, and vomiting may be clinically 
associated with sero-prevalence in the present study. 
Table 4. Sero-prevalence of DENV according to clinical characteristics 
Clinical characteristic Positive n (%) Negative n (%) P-value OR (95%CI) P-value 
Fever       
Yes 5 (1.2) 417 (98.8) § § 
§ 
No 0 (0.0) 0 (0.0)   
Headache      
Yes 4 (1.9) 204 (98.1) 0.167a 4.17 (0.46-37.68) 
NSb 
No 1 (0.5) 213 (99.5)  1.00 
Retro-orbital pain      
Yes 2 (5.7) 33 (94.3) 0.010a 1.00 
0.013a 
No 3 (0.8) 384(99.2)  7.75 (1.25-48.07) 
Muscle ache      
Yes 4 (3.5) 112 (96.5) 0.008a 10.89 (1.20-78.50) 
0.016a 
No 1 (0.3) 305 (99.7)  1.00 
Joint pain      
Yes 3 (4.1) 70 (95.9) 0.011a 7.43 (1.22-45.32) 
0.009a 
No 2 (0.6) 347 (99.4)    1.00 
Vomiting      
Yes 0 (0.0) 9 (100.0) 0.740a 1.00 NSb 
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No 5 (1.2) 408 (98.8)  ∞ 
Rash      
Yes 1 (0.7) 152 (99.3) 0.447a 0.43 (0.04-3.93) 
NSb 
No 4 (1.5) 409 (98.5)  1.00 
Bleeding diathesis      
Yes 0 (0.0) 8 (100.0) 0.755a 1.00 
NSb 
No 5 (1.2) 409 (98.8)  ∞ 
Abdominal pain      
Yes 0 (0.0) 9 (100.0) 0.740a 1.00 
NSb 
No 5 (1.2) 408 (98.8)  ∞ 
§no statistics are computed because fever is a constant. a=χ2 test. b= logistic regression analyses. ∞=OR could not be 
computed due to small sample sizes. NS=not significant. 
Associations between household factors and DENV 
seropositivity: The potential risk factors associated 
with dengue virus infection in patients with fever 
visiting the three selected health facilities in Trans-
Nzoia and Teso-south Districts: Based on previous 
studies [1], household level (housing conditions and 
surrounding), socio-economic, ITN use, other vector 
control activities and Yellow Fever vaccination were the 
main factors considered in the current study. Results 
revealed that walls with cracks (P=0.005) and place of 
storage of water vessel (P=0.002) in the households 
significantly altered DENV sero-positivity. Additional 
logistic regression analyses demonstrated that walls 
with cracks (OR; 8.75, 95% CI; 1.43-2.389, 
P<0.001), and place of storage of water vessel (OR; 
3.20, 95% CI; 2.78- 68.10, P=0.014) were 
significantly associated with DENV-2 sero-positivity 
(Table 5). 
Table 5: Household factors associated with DENV infection  
Risk factor 
Positive 
n (%) 
Negative 
n (%) P-value 
OR (95%CI) P-value 
HOUSE HOLD-LEVEL RISK FACTORS     
Type of house walls      
Bricks/stones/cement 1 (0.9) 114 (99) 0.922a 1.00  
Wood 0 (0) 2 (100)  ∞  
Mud 4 (1.3) 301 (98.7)  1.51 (0.16-13.69) NSb 
Walls with cracks      
Yes 3 (4.7) 61 (95.3) 0.005a 8.75 (1.43-53.47) <0.001b 
No 2 (0.6) 356 (99.4)  1.00  
Dumping site near house      
Yes 1 (0.6) 172 (99.4) 0.337a 0.35 (0.03-3.21) NSb 
No 4 (1.6) 245 (98.4)  1.00  
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Water storage vessel      
Covered 5 (1.2) 410 (98.8) 0.770a 1.00  
Not covered 0 (0) 7 (100)  ∞  
Place of storage of the vessel      
Inside house 1 (0.3) 320 (99.7) 0.002a 1.00  
Outside house 2 (9.1) 20 (90.9)  3.20 (2.78-68.10) 0.014b 
Both 2 (2.5) 77 (97.5)  8.31 (0.74-92.85) NSb 
Water bodies surrounding the 
house    
  
Yes 1 (0.5) 183 (99.5) 0.284a 0.18 (0.02-1.65) NSb 
No 4 (1.7) 234 (98.3)  1.00  
Vegetation surrounding the 
house     
  
Yes 4 (2.0) 198 (98.0) 0.148a 4.42 (0.49-39.91) NSb 
No 1 (0.5) 219 (99.5)  1.00  
Data are presented as n (%).a=χ2 test. b= logistic regression analyses.∞=OR could not be computed due to small 
sample sizes. NS=not significant. 
Associations between socio-economic factors and 
DENV seropositivity: Results on the socio-economic 
activities showed that burning of charcoal (P<0.0001) 
and farming (P=0.020) were significantly associated 
with DENV sero-positivity. However, the use of ITN 
(P=0.478), routine use of other vector control activities 
(P=0.767), types of vector control activities used 
(P=0.996) and Yellow Fever vaccination in the past 10 
years (P=0.787) were not associated with DENV sero-
positivity in this study population (Table 6). 
Table 6: Socio-economic factors associated with DENV infection  
Risk factor Positive;    n (%) 
Negative;    
n (%) P-value 
 
   OR (95% CI) P-value 
SOCIO-ECONOMIC ACTIVITIES-LEVEL 
RISK FACTORS 
    
Herd cattle      
Yes 1 (1.5) 64 (98.5) 0.775a 1.00 
NSb 
No 4 (1.1) 353 (98.9)  1.37 (0.15-12.53) 
Burn charcoal      
Yes  2 (11.1) 16 (88.9) <0.0001a 0.06 (0.01-0.38) 
<0.001a 
No 3 (0.7) 401 (99.3)  1.00 
Fetch water      
Yes 1 (1.4) 68 (98.6) 0.824a 0.77 (0.08-7.08) NSb 
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No 4 (1.1) 349 (98.9)  1.00 
Play near forest      
Yes 0 (0) 84 (100) 0.528a 1.00 
NSb 
No 5 (1.5) 333 (98.5)  3.52 (0.38-32.01) 
Farming      
Yes 4 (3.0) 130 (97.0) 0.020a 8.83 (1.97-79.78) 
0.024a 
No 1 (0.3) 287 (99.7)  1.00 
ITN use-level risk 
factor   
   
Yes 4 (1) 388 (99) 0.478a 3.59 (0.38-33.27) 
NSb No 1 (3.6) 27 (96.4)  1.00 
No response 0 (0) 2 (100)  0.34 (0.01-88.41) 
Use of other vector 
control-level risk 
factors 
  
  
 
Never 3 (1.1) 262 (98.9) 0.767a 1.39 (0.23-8.46) 
NSb Daily 2 (1.6) 125 (98.4)  1.00 
Occasionally 0 (0) 30 (100)  ∞ 
Type of vector control 
activities 
     
Herbs  0 (0) 6 (100) 0.996a ∞ 
NSb 
Insect repellants 0 (0) 14 (100)  ∞ 
Insecticide sprays 1 (1.4) 70 (98.6)  0.71 (0.07-6.99) 
Mosquito coils 1 (1.6) 63 (98.4)  0.79 (0.08-7.76) 
No control 3 (1.1) 264 (98.9)  1.00 
Yellow fever 
vaccination in the past 
10 years 
  
  
 
Yes 0 (0) 6 (0) 0.787a ∞ 
NSb 
No 5 (1.2) 411 (98.8)  1.00 
Data are presented as n (%).a=χ2 test. b= logistic regression analyses. ∞=OR could not be computed due to small 
sample sizes. NS=Not significant. 
Consistent with these observations, a further logistic 
regression analyses demonstrated that burning of 
charcoal (OR; 0.06, 95% CI; 0.01-0.38, P<0.001) 
and farming (OR; 8.83, 95% CI; 1.97-79.78, 
P<0.001) were significantly associated with DENV-2 
sero-positivity (Table 6). 
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Discussion 
Sero-prevalence of DENV in patients with fever 
visiting the study sites 
A sero-prevalence rate of 1.2% was obtained among 
the patients with febrile illness who visited the study 
health facilities. This suggests low prevalence of 
dengue in this population from Rift Valley and Western 
Provinces of Kenya. These findings are in agreement 
with other investigations of DENV conducted in Kenya 
[10], [11]. In these two studies, a seroprevalence rate 
of 1.0% (19/1624) was achieved [10] in eastern coast 
of Kenya, however, the serum was collected on healthy 
participants in the region. In the second survey [11], a 
seroprevalence rate of 1.1% (4/354) was obtained 
from healthy afebrile children in Kisumu of western 
Kenya. Despite the fact that study individuals had 
fever, a low sero-prevalence was recorded, indicating 
that DENV was not the main cause of febrile illness in 
this region. In yet another study carried out in Kilifi and 
Malindi districts in coastal Kenya [5] on febrile patients, 
higher prevalence rate of 20% (3/15) was obtained. 
However, these observations may not reflect on the 
true prevalence since the authors regarded their results 
as inconclusive due to cross-reactivity among 
flaviviruses [5], hence this made it difficult for them to 
determine the true sero-prevalence rate at that point in 
time. 
The current study only evaluated the presence of 
circulating DENV-2 and not the other three serotypes 
(DENV-1, DENV-3 and DENV-4). The focus of the 
current study was on DENV-2 since there was fear of 
an outbreak of this particular serotype following 
previous similar epidemic in the coastal region of 
Kenya in 1982 [5], [10], [11]. Moreover, a study 
carried out in Kenya on the serological evidence of 
arboviral infections among humans in Kenya [7], 
revealed that the evidence of DENV-2 was most 
common, followed by evidence of DENV-1, then 
DENV-3 and DENV-4. Furthermore, DENV-2 is now 
believed to be endemic in Kenya and Somalia [6]. 
Socio-demographic and clinical characteristics of 
patients with DENV 
The socio-demographic characteristics of febrile 
patients with dengue antibodies, visiting the three 
selected health facilities were also determined in the 
current study. Even though females had a higher sero-
positivity (1.7%; 4/240) compared to males (0.5%; 
1/182), these were not statistically different. These 
findings are comparable to a survey carried out in 
Nigeria [18] on the serological evidence of acute 
dengue virus infection among febrile patients attending 
Plateau State Specialist Hospital Jas, Nigeria, in which 
dengue infection was shown to be comparable 
between females and males. However, the current 
findings were inconsistent with previous observation in 
Mexico in which an increased risk was observed 
among women than in males [17]. A couple of other 
studies carried out in Rural Amazonia [27] 
demonstrated that the risk of past DENV infection at 
baseline and that of subsequent infections during the 
follow-up remained significantly higher among men, 
after controlling for migration patterns and travel history 
[27]. Furthermore, hospital-based studies in Asia have 
suggested that infections are more frequent in men 
[14]. Other studies carried out in India [9, [28-30] also 
suggest a higher prevalence of dengue infection 
among males than females. However, the biological 
bases for male-female differences in DENV infection 
rates remained undetermined [27]. It is hypothesized 
that such sex differences may be attributed to 
differences in immune responses elicited by DENV in 
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men and women patients [31] and that such sex-
related differences may reflect differential health care 
seeking behavior in males versus females. We 
hypothesize that lack of differences in sero-positivity in 
our population could be due to DENV patients having 
the same health-seeking behavior irrespective of the 
gender. This hypothesis is currently being investigated 
in our population. 
The current study also showed significant age 
differences in DENV infection rates (P=0.001) with 
most infections occurring in the age 21 to 60 years. 
This suggests a higher seroprevalence rate in adults 
compared to children. These observations were 
consistent with those of other studies carried out in 
Somalia [32], and in India (28-30). In contrast, other 
investigators revealed that dengue is a pediatric public 
health problem [15], [16], [33], [34]. In Americas, 
DENV syndromes occur in all age groups, however, 
majority of fatalities during epidemics occur in children 
[3]. In a previous study [9], it was concluded that the 
true endemicity of dengue is reached when the adult 
infection declines and occurs only through the new 
entrants into the population, that is, the children are 
affected more by the disease. However, in a 
longitudinal study on age-specificity of clinical dengue 
during primary and secondary infections [35], it was 
suggested that the estimated age-specific risk of 
clinical dengue increases as a function of age for both 
primary and secondary infections. The study further 
concluded that age is an important modulator of clinical 
dengue and further explains the recent increase in 
dengue notifications in aging countries such as in 
Southeast Asia [35]. Moreover, there is a paradox in 
the increase in adult patients resulting from a decline 
in the force of infection, which may be caused by 
various factors including time-dependent variations in 
epidemiological, ecological and demographic dynamics. 
It would be worthwhile to explore these hypotheses in 
the current study population. 
A DENV infection rate as stratified according to marital 
status was not found to be significant in this study. It is 
rather difficult to associate marital status in regard to 
DENV infections because DENV infections are vector-
borne and not sexually transmitted. In addition, no 
studies have the association between marital status 
and DENV infection. However, in the context of the 
current study population demographics, we 
demonstrate that all those individuals confirmed by 
PRNT to be sero-positive for DENV were married. 
The difference in occupation was found to be 
statistically significant (P=0.002), with majority of the 
infected persons being either employed or self-
employed, however, no evidences so far can exactly 
explain this outcome. Since self-reported responses to 
the structured questions were used to obtain the 
socio-demographic characteristics in this study, no 
detailed information on the type of work and its 
association with the exposures to DENV could be 
assessed properly. Therefore, the study could only 
determine these characteristics but could not clearly 
associate them to DENV infections. 
The current study also assessed place of habitat as a 
socio-demographic factor. Individuals were divided into 
rural or town habitation. However, the distribution of 
those living in rural versus urban and DENV sero-
positivity were comparable. Notwithstanding the 
insignificance, all the positive individuals hailed from 
the rural areas (1.4%). Historically, dengue has been 
reported as occurring predominantly among urban 
populations where density of dwellings and short flying 
distance of the vector create the right conditions for 
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transmission [2], [14], while other studies reveal that, 
dengue transmission and outbreaks occur in rural 
setting in both Asia, Latin America [14] and Amazonia 
[27]. The reasons for spread of dengue to rural areas 
have been highly associated with increased transport 
contact, mobility and spread of peri-urbanization [36]. 
The main symptoms associated with classical dengue 
fever [1] were used to determine the clinical 
characteristics in this study. Fever was the main entry 
point into the study. Majority of the participants who 
were sero-positive presented with headache (80%; 
4/5), muscle ache (80%; 4/5), joint pain (60; 3/5), 
retro-orbital pain (40%; 2/5) and rash (20%; 1/5) in 
decreasing frequency of presentation. In addition, none 
of the sero-positives had vomiting, abdominal pain and 
bleeding diathesis as presenting symptoms. However, 
associating these symptoms as presenting features 
specific to dengue was challenging. A review by Potts 
and Rothman was also unable to draw any clear 
conclusions on the signs and symptoms that can 
clinically distinguish dengue from other febrile illnesses 
[37]. Most developing countries have epidemics of 
febrile illnesses which can be confused with dengue 
fever [38].  
Collectively, the data obtained from the current study, 
provides insights into the difficulties in differential 
diagnosis of dengue infections which have been 
challenging due to its presentation with non-specific 
clinical symptoms. 
Risk factors associated with DENV infection 
Age (P=0.001) was the only individual risk factor 
significantly associated with seropositivity. Majority of 
the sero-positive individuals were between ages of 21 
to 60 years. Studies carried out in India, have reported 
15 to 45 years as the most affected age group [28]-
[30]. In Somalia, dengue has also been highly 
regarded as an adult disease [32]. Another study on 
age-specific risks of clinical dengue attack [35], 
revealed that adolescents and young adults are more 
likely to develop symptomatic dengue than younger 
individuals (such as primary school children). 
Infection with dengue is likely to be dependent on the 
quality of housing and use of prevention measures 
[39], [40]. In this study, the differences in housing 
conditions such as walls with cracks (P=0.005), place 
of storage of water vessels (P=0.002) were 
significantly associated with risks to dengue infections. 
In comparison to studies carried out in Thailand, 
housing conditions have greatly been shown to be a 
risk factor to dengue infection [39]. In the same study, 
it was also reported that storing of water vessels 
outside the house without covering displayed a higher 
risk for acquiring dengue, as they act as breeding sites 
for A. Aegypti [39]. In another study, dengue sero-
positivity and environmental factors were linked 
through location of households [40]. Despite findings in 
these previous studies, type of house walls (P=0.922), 
dumping site near the house (P=0.337), water storage 
vessel (P=0.770), water bodies surrounding the house 
(P=0.284) and vegetation surrounding the house 
(P=0.148) were not associated with risk to DENV 
sero-positivity in the current study. 
Studies carried out on the spatial patterns of dengue 
infection have also shown that persons living in houses 
surrounded by natural and agricultural vegetation had a 
lower risk of infection [40]; this is because some 
vegetation such as forests are not a favourite breeding 
place for Aedes mosquitoes [40]. The environment 
surrounding a person’s place of habitat can also act a 
good breeding site for Aedes mosquitoes [4]. However, 
contrary to these observations, these factors did not 
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alter DENV sero-positivity in our population. Most 
studies conducted on socio-economic factors, are 
normally ardent on the rich/poor indices [14]. The 
current study assessed individual socio-economic 
activities of the participants; herding of cattle 
(P=0.775), fetching water (P=0.824), playing near the 
forest (P=0.528) which were not associated with 
dengue sero-positivity. However, burning of charcoal 
(P<0.0001) and farming (P=0.020) were significantly 
associated with dengue seropositivity in the current 
study. Reasons for our observations could be 
attributed to the fact that these two (burning of 
charcoal and farming) are day time activities and 
Aedes mosquitoes bite mainly during day time [1]. 
Furthermore, sylvatic and peri-domestic cycles of 
DENV vectors have been reported [8] and activities 
such as herding of cattle, fetching water, playing near 
the forest even though not significant in this study, may 
act as risk factors subjecting people to infections with 
DENV. 
The use of insecticide-treated bed nets (ITN) was not 
significantly associated with dengue infections 
(P=0.478), in addition the routine use of other vector 
control activities (P=0.767) such as herbs, insects 
repellants, insecticide sprays, mosquito coils and lack 
of a vector control (P=0.996) did not significantly affect 
dengue sero-positivity. Use of ITN is normally 
mentioned as a prevention measure for dengue 
infection, nevertheless, this measure is not effective for 
dengue infection [39] as Aedes mosquitoes bite mainly 
during daytime [1]. Although studies have shown that 
the major mosquito vector for transmission of DENV is 
prevalent in the sylvatic and peri-domestic regions of 
western Kenya [8], the low seroprevalence (1.2%) of 
DENV in the rural settings, further supports the 
hypothesis of little autochthonous transmission in rural 
settlement. This observation has also been pointed out 
in other studies carried out on the rural Amazonian 
regions in the Americas such as Ramal do Granda [27] 
and Peruvian Amazonia [41] making vector control to 
be inappropriate for DENV control in rural areas where 
little autochthonous transmission occurs. Cross-
reactivity among flaviviruses could affect DENV 
antibody measurements in populations exposed to or 
immunized against Yellow Fever Virus (YFV) [26]. For 
instance, participants with antibodies to the vaccine 
strain of YFV (17DD) used in Brazil, detected by 
Haemagglutination Inhibition Assay (HIA) [42], were 
considerably more likely to have DENV IgG detected 
by ELISA. However, the current study was based on 
the confirmatory test results of PRNT and only 6 
(1.42%) of the study participants reported YFV 
vaccination over the past 10 years. DENV neutralizing 
antibodies were similarly prevalent in nonvaccinated 
individuals. This finding suggests that YFV vaccination 
has not substantially affected DENV neutralizing 
antibody measurements in the current study population 
(P=0.787). 
Conclusions 
Even though the current study reported a low sero-
prevalence rate of DENV, it still remains a potential 
hazard for public health in the study areas, as it may 
be an emerging circulating viral disease in the 
population [43]. It is therefore important to include 
DENV and possibly other endemic arboviruses in the 
differential diagnosis of febrile illness in Kenya. Even 
though standardized diagnostic criteria (IgM and IgG 
capture ELISA) are widely used in Kenya, the 
diagnosis of DENV infection remains inaccurate 
because several locally prevalent febrile illnesses may 
be misdiagnosed as dengue fever. For instance, in this 
study, the screening tests performed by indirect ELISA 
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designating the presence of IgM, IgG and IgA DENV 
antibodies found 62 of 422 serum samples to be 
positive, but only 5 sera were confirmed positive by 
PRNT. These findings underscore the need for 
laboratory confirmation of DENV infections for outbreak 
investigation and disease surveillance. 
Socio-demographic characteristics should be put into 
consideration when conducting dengue studies as they 
give an insight of the exposures and risk factors 
associated with dengue infections. Determining sex 
differences, both in infection and severity of disease, 
requires well-designed and targeted studies to capture 
both biological and social factors that drive disease 
patterns in a community. Hospital-based studies on 
population distributions and improved classification and 
diagnosis of dengue syndromes should be carried out 
to give more insight on age shift in dengue. Risk 
factors to dengue should be of keen interest as they 
predict the high and low risks regions in a country. 
Standard epidemiological techniques such as spatial 
studies of cases and careful patient histories could 
shed further light into risk factors and transmission of 
dengue. Furthermore, more studies should be carried 
out on DENV in Kenya using longitudinal study 
designs. The findings from this study could act as 
hypothesis to be tested further in order to obtain a 
clear picture of DENV prevalence in Kenya. 
Surveillance with good laboratory services serves as 
an ‘early warning system’ against impending outbreak 
of arbovirus infections. In addition, absence of a 
specific treatment for dengue fever management is 
mainly supportive, and since there are no vaccines 
currently available in the market, early diagnosis and 
vector control is the only method by which dengue can 
be effectively controlled. 
Limitations of the study 
This study only ascertained the evidence of DENV-2 
circulating in the study areas and not the other three 
serotypes (DENV-1, DENV-3 and DENV-4) due to 
limited funding and resources. Furthermore, most of 
our study population was drawn from KEMRI/CIPDCR 
Alupe clinic as most patients prefer to go for medical 
services in the Teso-South District region. Finally, 
Anderson Medical Centre was the only health facility 
that could be selected in Trans-Nzoia as it falls on the 
border belt between Kenya and Uganda and also 
samples that met our recruitment criteria of fever could 
only be found from this health facility. Future studies 
should explore beyond these health facilities and have 
a more representative sample size from each locality 
sampled. 
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